Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

DGAP-News: Eckert & Ziegler Starts Development Cooperation for Prostate Cancer Diagnosis

eqs_en 
0 0 13.02.20
DGAP-News: Eckert & Ziegler Starts Development Cooperation for Prostate Cancer Diagnosis
 

DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Alliance
Eckert & Ziegler Starts Development Cooperation for Prostate Cancer Diagnosis

13.02.2020 / 10:00
The issuer is solely responsible for the content of this announcement.

Berlin, 13 February 2020. The Berlin-based Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, S-DAX) and the Israeli Isotopia Molecular Imaging Ltd. (Isotopia) will in future work more closely together in the early detection of prostate cancer and to this end recently concluded an agreement on the joint development and approval of diagnostic reagents. As part of the agreement, the production of these substances shall soon be fully automated through the use of synthesis systems.

Eckert & Ziegler has long been developing and marketing so-called synthesis modules, which are used to prepare short-lived diagnostic reagents in hospitals for tumor diagnosis. So far, one important application field is the production of diagnostics for neuroendocrine tumors (NETs) on the basis of Gallium-68. The new strategic collaboration is intended to ensure that the synthesis modules also will be able to use Isotopia's simplified method to produce Gallium-68 based diagnostic reagents for the detection of prostate carcinomas in the future.

"Our synthesis modules simplify the work of physicians and medical physicists, so any expansion of the field of application makes sense," said Dr. Sven-Peter Heyn, Managing Director of Eckert & Ziegler Eurotope GmbH and responsible for the Lab Devices division. "We hope that this step will not only lead to higher sales of synthesis modules in the medium term, but also to a competitive advantage for our gallium generators, which are compatible to the devices.

About Eckert & Ziegler.
Eckert & Ziegler Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 800 employees, is one of the world's largest providers of isotope-related components for radiation therapy and nuclear medicine. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the SDAX index of Deutsche Börse.
Contributing to saving lives.

Contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, [email protected], www.ezag.de


13.02.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: +49 30 941084-138
Fax: +49 30 941084-112
E-mail: [email protected]
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 974629

 
End of News DGAP News Service

974629  13.02.2020 

fncls.ssp?fn=show_t_gif&application_id=974629&application_name=news&site_id=sharewise

Eckert & Ziegler Strahlen- und Medizintechnik AG Stock

€39.82
0.300%
The Eckert & Ziegler Strahlen- und Medizintechnik AG stock is trending slightly upwards today, with an increase of €0.12 (0.300%) compared to yesterday's price.
With 6 Buy predictions and not the single Sell prediction the community is currently very high on Eckert & Ziegler Strahlen- und Medizintechnik AG.
With a target price of 95 € there is potential for a 138.57% increase which would mean more than doubling the current price of 39.82 € for Eckert & Ziegler Strahlen- und Medizintechnik AG.
Show more
Like: 0
Share
eqs_en 
EQS Group is a leading international provider of regulatory technology in the fields of corporate compliance and investor relations. In working with EQS Group, thousands of companies worldwide inspire trust by fulfilling complex national and international disclosure obligations, minimizing risks and communicating transparently with stakeholders.




Legal notice

Comments

Not a member yet? Sign up for free!